HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIEHS

This article was originally published in The Rose Sheet

Executive Summary

Christopher Portier, PhD, is appointed to new role as National Institute of Environmental Health Sciences associate director for risk assessment, reflecting the agency's commitment to evaluating human health risks of chemicals, drugs and physical agents, NIEHS announces Jan. 10. In his new position, Portier will "oversee and coordinate risk assessment activities within the NIEHS and apply the results of toxicological studies to national and international" risk assessment efforts, agency says. Portier, who has been at NIEHS since 1981, most recently was National Toxicology Program associate director and served as NIEHS Environmental Toxicology program director. His work at NTP included developing its 21st Century roadmap, which identifies program directions in three areas - refining traditional toxicology assays, developing rapid, mechanism-based predictive screens for environmentally induced diseases and improving the overall utility of NTP products for public health decisions. He will be replaced as NTP associate director in the interim by Allan Dearry, PhD, NIEHS notes...

You may also be interested in...



‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel